Testosterone Therapy After RP May Work

Share this article:
Mohit Khera, MD, MBA, MPH
Mohit Khera, MD, MBA, MPH
TORONTO—Testosterone replacement therapy (TRT) may be effective in improving testosterone levels in hypogonadal men following radical prostatectomy (RP).

The findings are important because men with low testosterone may have a poor quality of life, said study investigator Mohit Khera, MD, MBA, MPH, assistant professor of urology at Baylor College of Medicine in Houston.

Among other signs and symptoms, patients suffer from depression, decreased libido, increased fat deposition, decreased muscle mass, and osteoporosis. Moreover, following RP, hypogonadal men are concerned about their erectile function, and low testosterone may impact their ability to have erections.

“Many clinicians and urologists are skeptical to put patients on testosterone after radical prostatectomy due to fear of unmasking or awaking dormant prostate cancer cells,” Dr. Khera told Renal & Urology News. “I believe that this paradigm may be slowly shifting. Currently, there are over 50,000 radical prostatectomies a year in the United States, and I think this is a subgroup of the population that has been typically denied testosterone replacement therapy.”

At the Sexual Medicine Society of North America annual meeting, he presented findings of a retrospective study that included 57 men initiated on TRT following RP. All had undetectable PSA and negative surgical margins prior to initiating TRT. The men had a mean age of 64 years (range 53-83 years) and men started TRT a mean 36 months after RP.

After an average follow-up of 13 months, mean testosterone values rose from 255 ng/dL before TRT initiation to 459 ng/dL. No significant change in PSA values were observed before and after initiating TRT. No patient had a biochemical PSA recurrence. When patients were stratified by Gleason score (6 or less, 7, and 8 or greater), the investigators observed no differences in PSA values before and after initiating TRT among the three groups.

Testosterone values rose from 276 to 639 ng/dL among patients with a Gleason score of 6 or less; from 262 to 350 ng/dL among patients with a Gleason score of 7; and from 139 to 538 ng/dl among patients with a Gleason score of 8 or higher.

Their study is the largest to date looking at testosterone replacement therapy after RP, Dr. Khera said, adding: “We have not had any PSA recurrences at this time.”

He and his colleagues have started enrollment for a randomized, placebo-controlled trial of TRT in post-RP patients at Baylor College of Medicine.

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Prostate Cancer

More in Prostate Cancer

Focal Prostate Cancer Therapy Safe, Feasible

Focal Prostate Cancer Therapy Safe, Feasible

In a study, none of the 62 men who had the treatment experienced erectile dysfunction or urinary incontinence.

MRI Highly Accurate in Detecting Significant Prostate Cancer

MRI Highly Accurate in Detecting Significant Prostate ...

Diffusion-weighted technique found to have a sensitivity and specificity of 89%-91% and 77%-81%, respectively.

BRCA2 Mutation Ups Prostate Cancer Death Risk

BRCA2 Mutation Ups Prostate Cancer Death Risk

In a study, the 12-year prostate cancer survival rate was 61.8% for men with the mutation versus 94.3% for those without it.